 |
馬里蘭州蓋瑟斯堡2024年2月18日 /美通社/ -- YS Biopharma Co.，有限公司（Nasdaq: YS）（「YS Biopharma」或「公司」），一家致力於發現、開發、製造和提供新一代傳染病和癌症疫苗和治療性生物製品的全球生物製藥公司，今天宣佈其於2024年2月16日在美國西雅圖舉行的特別股東大會的表決結果。公司股東對部分股東通過股東大會提出的以下每項決議投了反對票：
一、免去下列董事職務，並立即生效：（i）邵輝先生；（ii）譚擘先生；（iii）Ajit Shetty博士；（iv）Viren Mehta博士；（v）童少靖先生及（vi）余睿女士。
二、下列人士當選為董事，並立即生效：（i）張楠女士；（ii）張蘊女士；（iii）呂志強先生；（iv）李敬賢先生。
截至特別股東大會的股權登記日2024年2月8日營業結束時，公司已發行且流通在外的股本為188,327,959股普通股。持有97,272,542股普通股的股東於特別股東大會上進行了投票。特別股東大會上針對股東提交的每項決議的投票結果為零票贊成和97,272,542票反對。
本公司亦提醒投資者，切勿依賴張譯先生及其關聯人士就特別股東大會及本公司作出的虛假、未經證實及誤導性陳述，其相關英文陳述可見於：https://www.prnewswire.com/news-releases/shareholders-led-by-yi-zhang-announce-successful-results-of-removal-of-directors-and-election-of-new-directors-of-ys-biopharma-co-ltd-302064477.html。根據《公司章程》第63條，公司董事會主席應作為主席主持特別股東大會。此外，《公司章程》第88條特別股東大會應允許董事出席涉及任何罷免該董事的動議的會議並聽取其意見。董事會主席Ajit Shetty博士和公司董事Hui Shao博士被無理拒絕合法進入特別股東大會的原定舉行地點，即DLA Piper LLP位於美國華盛頓州西雅圖市的辦公室。
2024年2月16日，公司從開曼群島大法院獲得禁制令，禁制令要求張譯先生、張楠女士、張蘊女士、呂志強先生、李敬賢先生、劉媛女士和王冀民先生不得：
（1） 表明自己是公司的董事，或以公司董事身份採取任何措施或行使任何權力；
（2） 在向美國證券交易委員會或開曼群島或其他地方的任何其他政府機構發佈的任何新聞稿或提交的任何文件中聲稱（i）他們是公司董事和/或（ii）他們是根據有效組成的特別股東大會任命的董事；和
（3） 採取任何據稱源自任何董事決議或其以董事身份作出的其他決定的措施，或證明任何此類決議已適當通過或任何決定已有效作出。
該禁制令全文可在公司的「投資者關係」網站瀏覽，網址為https://investor.ysbiopharm.com/static-files/1c2b506b-557c-42bd-8045-c654e9bf6344
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKAR immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company's ability to source and retain talent, and the cash position of the Company following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance.
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by YS Biopharma from time to time with the U.S. Securities and Exchange Commission (「SEC」). These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading "Risk Factors" in the post-effective amendment No. 2 to Form F-1 filed with the SEC on January 23, 2024 which became effective on January 25, 2024, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: [email protected]
